Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
blog-list-cover
Recent blog posts
Polatuzumab Vedotin-Piiq in Diffuse Large B-Cell Lymphoma: NCT07744724 Clinical Landscape Report 2026
9 min read
Polatuzumab Vedotin-Piiq in Diffuse Large B-Cell Lymphoma: NCT07744724 Clinical Landscape Report 2026
11 September 2026
NCT07744724 clinical landscape for Diffuse Large B-Cell Lymphoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
Read →
Fludarabine Phosphate in Malignant Mesothelioma of Peritoneum: NCT07510815 Clinical Landscape Report 2026
9 min read
Fludarabine Phosphate in Malignant Mesothelioma of Peritoneum: NCT07510815 Clinical Landscape Report 2026
11 September 2026
NCT07510815 clinical landscape for Malignant Mesothelioma of Peritoneum: endpoints, sponsor, phase, geography, readouts, asset context and development white…
Read →
AbobotulinumtoxinA (Ipsen Biopharm Ltd) in Basal Cell Carcinoma: NCT07720726 Clinical Landscape Report 2026
9 min read
AbobotulinumtoxinA (Ipsen Biopharm Ltd) in Basal Cell Carcinoma: NCT07720726 Clinical Landscape Report 2026
11 September 2026
NCT07720726 clinical landscape for Basal Cell Carcinoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
Read →
203Pb-RMX-VH-PIB in Glioblastoma Multiforme: NCT07733674 Clinical Landscape Report 2026
9 min read
203Pb-RMX-VH-PIB in Glioblastoma Multiforme: NCT07733674 Clinical Landscape Report 2026
11 September 2026
NCT07733674 clinical landscape for Glioblastoma Multiforme: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
Read →
MWN-109 in Diabetes Mellitus, Type 2: NCT07801820 Clinical Landscape Report 2026
9 min read
MWN-109 in Diabetes Mellitus, Type 2: NCT07801820 Clinical Landscape Report 2026
11 September 2026
NCT07801820 clinical landscape for Diabetes Mellitus, Type 2: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
Read →
BreakVax (BreakBio Corp) in Triple Negative Breast Cancer: NCT07762703 Clinical Landscape Report 2026
9 min read
BreakVax (BreakBio Corp) in Triple Negative Breast Cancer: NCT07762703 Clinical Landscape Report 2026
11 September 2026
NCT07762703 clinical landscape for Triple Negative Breast Cancer: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
Read →
Verekitug in Severe asthma: NCT06966479 Clinical Landscape Report 2026
9 min read
Verekitug in Severe asthma: NCT06966479 Clinical Landscape Report 2026
11 September 2026
NCT06966479 clinical landscape for Severe asthma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
Read →
Avutometinib in Neurofibrosarcoma: NCT07743554 Clinical Landscape Report 2026
9 min read
Avutometinib in Neurofibrosarcoma: NCT07743554 Clinical Landscape Report 2026
11 September 2026
NCT07743554 clinical landscape for Neurofibrosarcoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
Read →
SHR-1139 in Plaque psoriasis: NCT07758075 Clinical Landscape Report 2026
9 min read
SHR-1139 in Plaque psoriasis: NCT07758075 Clinical Landscape Report 2026
11 September 2026
NCT07758075 clinical landscape for Plaque psoriasis: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
Read →
Trastuzumab Rezetecan in Platinum-Sensitive Ovarian Carcinoma: NCT07776171 Clinical Landscape Report 2026
9 min read
Trastuzumab Rezetecan in Platinum-Sensitive Ovarian Carcinoma: NCT07776171 Clinical Landscape Report 2026
11 September 2026
NCT07776171 clinical landscape for Platinum-Sensitive Ovarian Carcinoma: endpoints, sponsor, phase, geography, readouts, asset context and development white…
Read →
Tambotatug Pelitecan in Metastatic Pancreatic Cancer: NCT07803783 Clinical Landscape Report 2026
9 min read
Tambotatug Pelitecan in Metastatic Pancreatic Cancer: NCT07803783 Clinical Landscape Report 2026
11 September 2026
NCT07803783 clinical landscape for Metastatic Pancreatic Cancer: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
Read →
Eloralintide in Obesity: NCT07808060 Clinical Landscape Report 2026
9 min read
Eloralintide in Obesity: NCT07808060 Clinical Landscape Report 2026
11 September 2026
NCT07808060 clinical landscape for Obesity: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
Read →